Correspondence 0000950170-24-128772 from enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc.
Date: Nov. 19, 2024 · CIK: 0001980845 · Accession: 0000950170-24-128772
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283201
Letter
enGene Holdings Inc.
4868 Rue Levy, Suite 220
Saint-Laurent, QC H4R2P1
(514) 332-4888
November 19, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Chris Edwards
Re: enGene Holdings Inc.
Registration Statement on Form S-3
Filed November 13, 2024
File No. 333-283201
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, enGene Holdings Inc. hereby requests acceleration of the effective date of the above-referenced registration statement on Form S-3, so that such registration statement may become effective at 4:00 P.M. (Washington, D.C. time) on November 21, 2024, or as soon as practicable thereafter.
The Registrant hereby authorizes Maria L. Sasinoski, of Morgan, Lewis & Bockius LLP to orally modify or withdraw this request for acceleration.
Please contact Maria L. Sasinoski of Morgan, Lewis & Bockius LLP at (412) 560-7482 or maria.sasinoski@morganlewis.com with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.
enGene Holdings Inc.
By: /s/ Ronald H.W. Cooper
Name: Ronald H.W. Cooper
Title: Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP enGene Holdings Inc. 4868 Rue Levy, Suite 220 Saint-Laurent, QC H4R2P1 (514) 332-4888 November 19, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Chris Edwards Re: enGene Holdings Inc. Registration Statement on Form S-3 Filed November 13, 2024 File No. 333-283201 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, enGene Holdings Inc. hereby requests acceleration of the effective date of the above-referenced registration statement on Form S-3, so that such registration statement may become effective at 4:00 P.M. (Washington, D.C. time) on November 21, 2024, or as soon as practicable thereafter. The Registrant hereby authorizes Maria L. Sasinoski, of Morgan, Lewis & Bockius LLP to orally modify or withdraw this request for acceleration. Please contact Maria L. Sasinoski of Morgan, Lewis & Bockius LLP at (412) 560-7482 or maria.sasinoski@morganlewis.com with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted. enGene Holdings Inc. By: /s/ Ronald H.W. Cooper Name: Ronald H.W. Cooper Title: Chief Executive Officer